December 26, 2021
1 min watch
Save
VIDEO: Determining risk of long-term pacritinib for myelofibrosis
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Aaron T. Gerds, MD, MS, discusses data presented at ASH Annual Meeting and Exposition about the long-term treatment with pacritinib in patients with advanced myelofibrosis.
“Extended treatment does not seem to increase the risk of adverse events,” said Gerds, assistant professor of medicine at Cleveland Clinic Taussig Cancer Institute and medical director of Case Comprehensive Cancer Center,
Reference
- Harrison CN, et al. Abstract 3649. Presented at: ASH Annual Meeting & Exposition; Dec. 11-14, 2021; Atlanta.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Gerds reports consulting for AbbVie, Bristol Myers Squibb, Constellation Pharmaceuticals, Novartis, PharmaEssentia and Sierra Oncology; and providing research support for Accurate Pharmaceuticals, Constellation Pharmaceuticals, CTI BioPharma, Imago BioSciences, Incyte Corporation and Kratos Pharmaceuticals.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.